75 completed, 33 recruiting, 29 unknown, 14 not yet recruiting. 70 Phase 2, 57 Phase 3, 30 Phase 1, 13 Phase 4, 9 Not applicable.
Follow baricitinib: new trials by email Literature Review of baricitinib trials Research Report on baricitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment Interruption Baricitinib 2 MG, Sirolimus 2 MG, Placebo of baricitinib 2 MG - HIV-1-infection | Phase 2 | Not yet recruiting | ANRS, Emerging Infectious Diseases | 191 | 2027-05-01 | 2026-10-19 |
| Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis baricitinib - Hyper IgE Syndrome From STAT3 Mutation, Job s Syndrome | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2026-10-27 | 2026-10-22 |
| Therapeutics for Moderate and Severe Dengue Placebo, Dexamethasone, N-Acetylcysteine - Dengue, Severe Dengue | Phase 3 | Not yet recruiting | Oxford University Clinical Research Unit, Vietnam | 8800 | 2026-10-01 | 2026-04-21 |
| Baricitinib Curative Repression of HIV-1 Antiretroviral Therapy (ART), Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg - HIV Infection, HIV | Phase 2 | Not yet recruiting | Emory University | 35 | 2026-10-01 | 2026-08-17 |
| JAK Signaling in Depression and Cognition in Male Football Players Baricitinib - Depressive Symptoms, Cognitive Symptom | Phase 2 | Recruiting | Emory University | 30 | 2026-10-01 | 2026-09-24 |
| Precision Medicine Adaptive Network Platform Trial in Hypoxemic Acute Respiratory Failure Simvastatin, Baricitinib - ARDS (Acute Respiratory Distress Syndrome), Acute Hypoxic Respiratory Failure | Phase 2 | Not yet recruiting | University of Colorado, Denver | 300 | 2026-09-01 | 2026-10-08 |
| A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult Volunteers Upadacitinib, Tofacitinib, Baricitinib - Healthy Volunteers | Phase 1 | Recruiting | AbbVie | 60 | 2026-08-26 | 2026-09-28 |
| Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial Tocilizumab, Baricitinib, Anakinra - Sepsis | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 2000 | 2026-07-09 | 2026-10-20 |
| TPO-RA Plus Baricitinib vs. TPO-RA for ITP Baricitinib, TPO-RA - ITP - Immune Thrombocytopenia | Phase 2 | Not yet recruiting | Peking University People's Hospital | 100 | 2026-07-01 | 2026-06-25 |
| Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis Baricitinib 4 MG - Active Non-anterior Non-infectious Uveitis | Phase 3 | Not yet recruiting | University Hospital, Rouen | 33 | 2026-07-01 | 2026-06-08 |
| Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica Abrocitinib, Upadacitinib, Baricitinib - Atopic Dermatitis, Atopic Dermatitis (AD) | Not yet recruiting | Caja Costarricense de Seguro Social | 50 | 2026-05-01 | 2026-04-08 | |
| Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration placebo, Baricitinib tablets, IBI3013 - Healthy, Active Non-segmental Vitiligo | Phase 1 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 160 | 2026-04-18 | 2026-04-28 |
| Biologics in Folliculitis Decalvans : an Adaptative Trial Research Adalimumab, Ustekinumab, Baricitinib - Folliculitis Decalvans (FD) | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 120 | 2026-04-01 | 2025-12-05 |
| A Trial of Baricitinib in Patients With Cardiac Sarcoidosis Baricitinib (LY3009104) 4 mg - Cardiac Sarcoidosis | Phase 2 | Not yet recruiting | Stanford University | 10 | 2026-04-01 | 2026-02-10 |
| Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial 2mg Baricitinib, 4mg Baricitinib, Placebo - Acute Ichemic Stroke, Anterior Cerebral Artery Stroke | Phase 2 / Phase 3 | Not yet recruiting | The First Affiliated Hospital of University of Science and Technology of China | 750 | 2026-03-17 | 2026-03-04 |
| Baricitinib for Post-HSCT Persistent Thrombocytopenia Baricitinib - Persistent Thrombocytopenia, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 1 / Phase 2 | Recruiting | Peking University People's Hospital | 28 | 2026-03-09 | 2026-09-16 |
| Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement Baricitinib - Kohlmeier-Degos Disease, Malignant Atrophic Papulosis | Phase 2 | Recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 12 | 2026-02-18 | 2026-09-18 |
| A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) Baricitinib, Placebo - Diabetes Mellitus, Type 1 | Phase 3 | Recruiting | Eli Lilly and Company | 300 | 2026-02-05 | 2026-10-08 |
| A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults Baricitinib, Placebo - Diabetes Mellitus, Type 1 | Phase 3 | Recruiting | Eli Lilly and Company | 150 | 2026-01-12 | 2026-10-08 |
| Baricitinib Effects on Procoagulant State in Rheumatoid Arthritis Baricitinib - Rheumatoid Arthritis | Phase 4 | Not yet recruiting | Tanta University | 100 | 2026-01-01 | 2026-01-22 |
Showing 20 of 177. Sign in to see all of them.
Arthritis, Rheumatoid (32) · COVID-19 (24) · Dermatitis, Atopic (15) · Eczema (9) · Alopecia Areata (7) · Coronavirus Infections (5) · Lupus Erythematosus, Systemic (5) · Pneumonia (5) · Arthritis (4) · Dermatomyositis (4) · Inflammation (4) · Purpura, Thrombocytopenic, Idiopathic (4) · Alopecia (3) · Arthritis, Juvenile (3) · Depression (3)
Eli Lilly and Company (56) · Assistance Publique - Hôpitaux de Paris (6) · Peking University People's Hospital (6) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (4) · Emory University (4) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Peking Union Medical College Hospital (3) · Assiut University (2) · Instituto de Investigación Hospital Universitario La Paz (2) · South Valley University (2) · Tang-Du Hospital (2) · Tianjin Medical University General Hospital (2) · University Hospital, Brest (2) · University of Colorado, Denver (2) · Vastra Gotaland Region (2)
United States (66) · Japan (33) · United Kingdom (33) · Spain (32) · France (31) · China (27) · Italy (26) · Germany (24) · Mexico (21) · Poland (20) · Argentina (19) · South Korea (19) · Australia (18) · Belgium (18) · Czechia (17)
Andrew H Miller, MD (3) · Jennifer Felger, PhD (2) · William Tyor, MD (2) · Xiaohui Zhang, MD (2) · Xiaomei Leng, Dr. (2) · Aaron R Mangold, MD (1) · Adeline Vanderver, MD (1) · Ahmed Elshafeey, Ph.D. Pharma (1)
PMID 34706874, PMID 29463520, PMID 33826132, PMID 34473343, PMID 36255569, PMID 30219772, PMID 30842122, PMID 30058112, PMID 32414425, PMID 36749121, PMID 33687069, PMID 34028703, PMID 34275122, PMID 34526397, PMID 34688290, PMID 35695334, PMID 27689735, PMID 27723271, PMID 29680881, PMID 30902094, PMID 31040122, PMID 31233281, PMID 32678530, PMID 33222559, PMID 33306283, PMID 33394942, PMID 33899152, PMID 35334197, PMID 35786528, PMID 36442063, PMID 36763878, PMID 36855020, PMID 37015757, PMID 37381691, PMID 37489818, PMID 37556146, PMID 37991697, PMID 38904749, PMID 40214720, PMID 40305472, PMID 42825995, PMID 22263004, PMID 25431052, PMID 26834213, PMID 27028914, PMID 27799159, PMID 28199814, PMID 28405473, PMID 28440680, PMID 28798049
2017 (10), 2023 (4), 2025 (4), 2018 (3), 2015 (2), 2019 (1), P30CA014089 (1), R01AG085873 (1), R01MD016401 (1), R01MH128158 (1), R01MH128872 (1), R01MH140180 (1)